Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valeant, Morgan Stanley, Genocea: Stocks In The Spotlight For The Wrong Reasons Today

Page 1 of 2

It’s Monday and shareholders of Morgan Stanley (NYSE:MS), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and Genocea Biosciences Inc (NASDAQ:GNCA) are certainly on alert as the value of their shares has changed substantially since Friday’s close, and not for the better. Let’s take a closer look at the catalysts causing the negative moves on these stocks and what elite investors think of them.


But first, a little about ourselves. We at Insider Monkey monitor hedge fund sentiment. Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds have beaten the S&P 500 Index by more than 53 percentage points since the end of August 2012. These stocks returned a cumulative of 102% vs. a 49% gain for the S&P 500 Index (see the details here). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

Morgan Stanley (NYSE:MS) is down by 5.5% after the investment bank reported disappointing third quarter earnings. Earnings missed analysts’ expectations by $0.29 per share while revenues missed estimates by $1.21 billion. CEO James P. Gorman said:

“The volatility in global markets in the third quarter led to a difficult environment, impacting in particular our Fixed Income business and our Asia Merchant Banking business.”

Apparently, the era of cheap debt coming to an end did not help the company’s M&A division nearly enough to offset the trading unit’s decline. Given Goldman Sachs trades at a lower forward P/E than Morgan Stanley and Goldman Sachs’ earnings results were better, it’s hard to get excited about the stock after this latest earnings report.

Follow Morgan Stanley Institutional Liquidity Funds (NYSE:MS)
Trade (NYSE:MS) Now!

Genocea Biosciences Inc (NASDAQ:GNCA), a company developing T cell-directed immunotherapies and vaccines, is down by 27% after the company’s universal vaccine candidate against pneumococcus, GEN-004, failed to achieve the primary endpoints in a phase 2a trial. Management will remove GEN-004 from its near-term plans and will instead refocus the company’s resources on the ongoing Phase 2 program for GEN-003, the company’s immunotherapy for genital herpes.

Follow Genocea Biosciences Inc. (NASDAQ:GNCA)
Trade (NASDAQ:GNCA) Now!

On the next page, we analyze why Valeant is getting beat up some more today.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!